Vismodegib (Erivedge®) is indicated for the treatment of adult patients with locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy or metastatic basal cell carcinoma.
Rapid Review
| Commenced | Completed | Outcome |
| 02/05/13 | 20/05/13 | Full Pharmacoeconomic Evaluation Recommended |
Pharmoeconomic Evaluation
| Commenced | Completed | Outcome |
| 16/09/2013 | 21/01/2014 | Reimbursement not recommended |
The HSE has approved reimbursement following confidential price negotiations October 2017.